.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BC02_Raxibacumab.Raxibacumab

Information

Raxibacumab is a human monoclonal antibody that binds to the protective antigen of Bacillus anthracis, the bacterium that causes anthrax. It is used to treat inhalational anthrax in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or appropriate. Raxibacumab is approved by the FDA for these uses.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers following single intravenous infusion.

References

1. Oosterholt, SP, & Della Pasqua, O (2021). Population pharmacokinetics of raxibacumab in healthy adult subjects. British journal of clinical pharmacology 87(12) 4718–4725. DOI:10.1111/bcp.14894 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33973655

2. Skoura, N, et al., & Tan, LK (2020). Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study. The Lancet. Infectious diseases 20(8) 983–991. DOI:10.1016/S1473-3099(20)30069-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32333847

Revisions

• 06/2025 initial generated model